{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-076464","form_type":"8-K","ticker":"ZBIO","cik":"0001953926","company_name":"Zenas BioPharma, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.685523+00:00","generated_at":"2026-05-17T14:54:45.264783+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zenas BioPharma Q2 net loss $52.2M; cash $274.9M; obexelimab trials on track","bullets":["Net loss of $52.2M for Q2 2025, compared to $38.0M in Q2 2024.","Cash, cash equivalents and investments of $274.9M as of June 30, 2025; expected runway into Q4 2026.","Phase 3 INDIGO trial (IgG4-RD) topline results expected around year-end 2025.","Phase 2 MoonStone trial (RMS) enrollment completed; results early Q4 2025.","Phase 2 SunStone trial (SLE) enrollment expected by year-end 2025; topline mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-076464","json":"https://secwatch.observer/filing/0001104659-25-076464.json","markdown":"https://secwatch.observer/filing/0001104659-25-076464.md","text":"https://secwatch.observer/filing/0001104659-25-076464.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1953926/000110465925076464/0001104659-25-076464-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1953926/000110465925076464/tm2523154d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:54:45.264783+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}